Redeye comments on NeoDynamics Q3 report and hopes to see its commercial roll-out leveraged on its study participants in the coming quarters. However, the anticipated FDA application continues to be uncertain, timing-wise, and an equity issue is to expect in H1 22. The stock is likely to await these events before it can begin a more sustainable upwards valuation.

Länk till analysen